Navigation Links
Study Suggests Risperidone Long-Acting Injection Combined with Standard Treatment Helped Delay Time to Relapse in Patients with Bipolar Disorder
Date:2/4/2008

inistered once every two weeks by a healthcare professional and avoids the need for patients to remember to take daily antipsychotic medications. "

In the study, 139 patients were randomized to receive either RLAI 25-50mg intramuscular injection (n=72), or placebo injections (n=67) adjunctive to standard treatment. Patients receiving RLAI plus standard treatment were eligible to enter the double blind phase of the trial if they met predefined criteria(a) for being stable the last four weeks of the 16-week open-label stabilization phase.

In the study, Frequently Relapsing Bipolar Disorder: Evidence for an Effective Treatment Using Adjunctive Risperidone Long-Acting Injectable, 67% of patients randomized received a 25 mg dose of RLAI, 29% received a 37.5 mg dose and 4% received a 50 mg dose, administered once every two weeks.

The primary efficacy endpoint in the double-blind phase of the trial was the time from randomization to relapse, where relapse was defined as the first occurrence of a mood episode as determined by an independent Relapse Monitoring Board (RMB).(b)

The results showed a significant difference in time to relapse (p=0.004), with a more than two-fold higher risk of relapse in the placebo group (47.8%) than the RLAI group (22.2%). In addition, scores on the Clinical Global Impression-Bipolar-Severity (CGI-BP-S) scale for overall bipolar disorder and the Clinical Global Impression-Bipolar-Change (CGI-BP-C) scale worsened significantly (p<0.05) in the placebo group compared with the RLAI group.

Treatment-emergent adverse effects (TEAEs) occurred more frequently in the group that received placebo and standard treatment (76.1%) than in the group that received RLAI and standard treatment (70.8%), as did serious adverse effects (placebo=19.4%; RLAI = 13.9%). The most common TEAEs (greater than 5%) in the double-blind phase were tremor (RLAI = 23.6%; placebo = 16.4%), insomnia (RLAI = 19.4%; placebo = 23.9%), muscle rigidity
'/>"/>

SOURCE Janssen
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Study Finds Widespread Vitamin and Mineral Use Among Cancer Survivors, Although Benefits of Such Use Remain Unclear
2. The LANCET Published ENDORSE, the Largest Multinational Study Showing That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE Prophylaxis
3. MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
4. Venture Capitalists Bullish on Greentech and Biotech, KPMG Study Says
5. Study Shows Coronado Biosciences Bcl-2 Inhibitor, Apogossypol, is More Efficacious, Less Toxic than Gossypol in Animal Models
6. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
7. Kaiser Permanente Study Shows Newer, Stronger Evidence That Caffeine During Pregnancy Increases Miscarriage Risk
8. Center for Molecular Medicine Selected to Provide DNA Analysis for Childrens Oncology Group Leukemia Study
9. Phase I Safety and Tolerability Study With EVT 302 Successfully Completed
10. Study Examines Media Preferences of Life Scientists in Applied Markets
11. Triage study challenges notions of emergency medical response to disaster
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... 22, 2014 Patients who were treated with a statin ... were significantly more likely to survive than those who ... JAMA Neurology . This study was conducted by ... of cholesterol-lowering statins can improve survival in victims of ... or obstruction of a blood vessel that blocks blood ...
(Date:9/22/2014)... NEW YORK and SANTA CLARA, ... Health Corp. (NASDAQ: WBMD ), the leading ... a new WebMD/Medscape survey that provide novel ... role in aiding diagnosis and care.  Dr. Eric ... genomics and digital medicine, who serves as both Editor-in-Chief ...
(Date:9/22/2014)... components developed by researchers at the USC Viterbi ... build a 3-D microfluidic system quickly and cheaply ... , Microfluidic systems are used in many ... manipulate small volumes of fluids for use in ... detection, clinical diagnostic testing, and synthetic chemistry. Traditionally, ...
(Date:9/22/2014)... tumor cells (CTCs) in a mouse model of pancreatic ... groups of CTCs, including significant differences from the primary ... metastases. In their study reported in the Sept. ... the Massachusetts General Hospital (MGH) Cancer Center identified several ... that may prove to be targets for improved treatment ...
Breaking Biology Technology:Statin use during hospitalization for hemorrhagic stroke associated with improved survival 2WebMD/Medscape Digital Technology Survey Reveals Unique Insights Into How Patients and Physicians Perceive the Role, Potential and Risks Associated with Digital Health Technologies 2WebMD/Medscape Digital Technology Survey Reveals Unique Insights Into How Patients and Physicians Perceive the Role, Potential and Risks Associated with Digital Health Technologies 3WebMD/Medscape Digital Technology Survey Reveals Unique Insights Into How Patients and Physicians Perceive the Role, Potential and Risks Associated with Digital Health Technologies 4Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 2Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 3Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 4Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 5Massachusetts General study reveals gene expression patterns in pancreatic CTCs 2Massachusetts General study reveals gene expression patterns in pancreatic CTCs 3
... Patent 7,507,704 issued on 03/24/09 to NexGen Biomedical, ... an improved method of treating lung, brain, pancreatic, breast ... known as HER1 overexpression (also called EGFR or c-ErbB-1). ... concurrent HER1 blocker / S-Phase cytotoxic protocols achieve only ...
... -- WuXi AppTec (NYSE: WX ), a ... with operations in China and the United States, today,announced ... (Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO ) , ... joined WuXi AppTec as Vice President of Toxicology and,Head ...
... Release Hospitals Highlights Early Clinical Benefits and Patient ... MASI ), the inventor of Pulse ... announced today that it has initiated the full ... hemoglobin (SpHb(TM)) monitoring technology. As the first noninvasive ...
Cached Biology Technology:Patent for Making Combination Chemotherapy Work Better 2WuXi AppTec Welcomes Three Senior Professionals 2Masimo Initiates Full Market Release of First-Ever Noninvasive Continuous Hemoglobin Monitor 2Masimo Initiates Full Market Release of First-Ever Noninvasive Continuous Hemoglobin Monitor 3Masimo Initiates Full Market Release of First-Ever Noninvasive Continuous Hemoglobin Monitor 4Masimo Initiates Full Market Release of First-Ever Noninvasive Continuous Hemoglobin Monitor 5Masimo Initiates Full Market Release of First-Ever Noninvasive Continuous Hemoglobin Monitor 6
(Date:9/23/2014)... Although the immediate welfare consequences of removing infant chimpanzees ... about the long-term impacts of this type of early ... Park Zoon observed 60 chimpanzees and concluded that those ... and raised by humans as pets or performers are ... , The multi-institutional research project, published today in the ...
(Date:9/22/2014)... the University of Chicago have shown that after a ... a handful of pathogenic microbe species remain behind in ... discovered that some can become deadly when provoked by ... , The findings, published in mBio , the ... may lead to better monitoring and treatment of ICU ...
(Date:9/22/2014)... Many native species have vanished from tropical islands ... scientists have discovered how fossils can be used ... lies in organic materials found in fossil bones, ... according to a new study available online and ... of Herpetology . Pre-human island ecosystems provide vital ...
Breaking Biology News(10 mins):Chimpanzees raised as pets or performers suffer long-term effects on their behavior 2Critically ill ICU patients lose almost all of their gut microbesand the ones left aren't good 2Critically ill ICU patients lose almost all of their gut microbesand the ones left aren't good 3Answer to restoring lost island biodiversity found in fossils 2
... Hopkins neuroscientists has worked out how some newly discovered ... with the brain. The report appears online this week ... are a small number of nerve cells in the ... in the retinarods and conesmelanopsin-containing cells are not used ...
... While examining patterns of DNA modification in lung cancer, ... is a surprising new mechanism. They say that "silencing" of ... impairment in genome-wide changes in cells, contributing to cancer development ... Cancer Research , a journal of the American Association ...
... will be one step closer to better drought-tolerant soybean ... database of all proteins and metabolites in soybeans. Once ... in proteins and metabolites in soybeans grown under drought ... the recently released soybean genome, scientists will have a ...
Cached Biology News:Bright lights, not-so-big pupils 2Bright lights, not-so-big pupils 3In lung cancer, silencing one crucial gene disrupts normal functioning of genome 2In lung cancer, silencing one crucial gene disrupts normal functioning of genome 3Soybean database will help breeders engineer better-performing plants 2
Phosphatidylinositol transfer protein beta isoform (PtdIns transfer protein beta) (PtdInsTP) (PI-TP-beta). [Source:Uniprot/SWISSPROT;Acc:P48739] Antigen: Recombinant Protein Epitope Signature Tag...
Desmosomal Protein Immunogen: Full length, native protein purified from human epidermal keratins. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Mouse monoclonal [SPM217] to Secretory Component Glycoprotein ( Abpromise for all tested applications)....
Mouse monoclonal [3G8] to MDMA ( Abpromise for all tested applications)....
Biology Products: